EXOZ · Exozymes Inc.
$5.77
+0.01 (+0.17%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Given the Company's current operating cash burn, its existing working capital as of June 30, 2026, is not sufficient to fund operations for twelve months from the date these condensed unaudited consolidated financial statements are issued, and management has concluded that substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$57.96M
Shares
9.28M
Volume · Oct 2
2116
Avg daily vol (3M)
7313
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.77
Open$5.87
Day$5.76–6.00
52W close$4.40–16.50
Avg vol 30d6K
Short int20K · 0.2% float · 3.1d
Short vol36%
DataNov 2024–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$10.19M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-2,563.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$5.65M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.4%
Year over year · more shares
Price change (1Y)
-56.6%
Trailing year
Short interest
0.2%
Latest settlement · 3.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−32%
below
Price vs 50-day avg
−4%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
11%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−51%
trailing
YTD return
−47%
this year
Relative strength
−63%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+29% holders QoQ · +2 funds added
Insider flow
Accumulating
Net +$6.4K over 90 days · 0% sells
Short interest
Falling
0.22% of float · ▼ -6.4% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — mid 1-yr range
Squeeze score
44
elevated · 0–100
Fundamentals
EPS growth
−22%
Y/Y
Free cash flow
$-6.7M
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−73%
past year
ATR
9.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−32%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
11%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+29% holders QoQ · +2 funds added
Insider flow
Accumulating
Net +$6.4K over 90 days · 0% sells
Short interest
Falling
0.22% of float · ▼ -6.4% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $4
Now $6 · 11%
Range high $17
vs 200-day avg -32%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EXOZ
this stock
Exozymes Inc.
|
$57.96M | -47.1% | — | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EXOZ | -7.6% | -15.2% | -50.7% | -1.0% | -47.1% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -7.4% | -14.7% | -62.9% | -2.0% | -59.9% |